Stock HUGE FSD PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases FSD Pharma Inc.

Equities

HUGE

CA35954B4047

Market Closed - Canadian Securities Exchange
Other stock markets
 20:48:47 28/06/2024 BST 		5-day change 1st Jan Change
0.22 CAD -6.38% Intraday chart for FSD Pharma Inc. -8.33% -81.67%
06-28 FSD Pharma $2 Million Arbitration Award Upheld by Federal Court Against Former CEO MT
06-28 Sector Update: Health Care Stocks Decline in Late Afternoon Trading MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 in Australia
AQ
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication
AQ
FSD Pharma : Provides Corporate Update - Form 6-K
PU
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd
AQ
FSD Pharma : Provides Update on Celly Nu’s New Packaging for unbuzzd(TM) - Form 6-K
PU
FSD Pharma : Condensed consolidated interim financial statements - Form 6-K
PU
FSD Pharma : Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia - Form 6-K
PU
FSD Pharma Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd in an Induced State of Alcohol Intoxication
AQ
FSD Pharma : Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy ofunbuzzd™ in an Induced State of Alcohol Intoxication - Form 6-K
PU
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd
AQ
FSD Pharma Provides another Update on Celly Nu's Anticipated Launch of unbuzzd
AQ
FSD Pharma : Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products - Form 6-K
PU
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
AQ
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
NE
FSD Pharma Signs the Agreement With iNGENu CRO to Conduct a Clinical Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adults
AQ
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 at Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum
AQ
FSD Pharma : Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum - Form 6-K
PU
FSD Pharma Announces Debt Settlement
AQ
FSD Pharma Signs Agreement with Ingenu CRO to Conduct a Clinical Trial to Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd
AQ
FSD Pharma Announces US ATM Offering
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HUGE Stock
  4. News FSD Pharma Inc.
  5. Press Releases